Results 171 to 180 of about 5,794,212 (304)

Health Literacy Impairment and Awareness of Clinical Pharmacist Services Among Geriatric Tertiary-Care Outpatients: A Cross-Sectional Study. [PDF]

Healthcare (Basel)
Vasudevan R, Alshahrani A, Devanandan P, Kandasamy G, Alqahtani SS, Alobaid HE, Alsurraya HM, Alshahrani MS, Alshahrani RJ, Alwaymani AA, Alghamdi LK.   +10 more
europepmc   +1 more source

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

Molecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler, Bilal A. Lone, Ecem Unal, A. Rouf Banday   +3 more
wiley   +1 more source

Research by Academic Clinical Pharmacists [PDF]

Drug Intelligence & Clinical Pharmacy, 1982
openaire   +2 more sources

Effect of clinical pharmacist consultation on postoperative pain, quality of life, and patient satisfaction after pacemaker implantation: A randomized controlled trial. [PDF]

Explor Res Clin Soc Pharm
Alhaj AM, Bassiouny EA, Farid SF.
europepmc   +1 more source

p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer‐relevant paralog interplay

Molecular Oncology, EarlyView.
This study identifies ARHGAP5, in addition to the frequently mutated ARHGAP35, as significantly mutated in endometrial cancer. Mutations in both genes co‐occur and are associated with their correlated downregulation. Functional CRISPR studies show that both paralogs regulate similar pathways, including actin cytoskeleton organization.
Mathilde Pinault, Capucine Heraud, Mélissa Correia de Oliveira, Véronique Neaud, Valérie Valesco, Valérie Prouzet‐Mauleon, Béatrice Turcq, Jean‐William Dupuy, Anne‐Aurélie Raymond, Sabrina Croce, Frédéric Saltel, Valérie Lagrée, Violaine Moreau   +12 more
wiley   +1 more source

Impact of clinical pharmacist interventions on drug-related problems in hospitalised patients with renal dysfunction: a quasi-experimental study. [PDF]

Sci Rep
Özmen Ö, Bektay MY, Karatoprak C, İzzettin FV.   +3 more
europepmc   +1 more source

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

Molecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic   +9 more
wiley   +1 more source

Impact of Clinical Pharmacist Interventions on Medication Safety and Therapy Optimization in a Tertiary Care Hospital. [PDF]

Cureus
Rahim S.
europepmc   +1 more source

Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer

Molecular Oncology, EarlyView.
Circulating microRNA profiles distinguish nonmalignant Lynch syndrome from cancer‐associated Lynch syndrome, sporadic colorectal cancer, and healthy controls. Age‐stratified analysis reveals disease‐specific regulatory states, and a six‐miRNA panel shows concordant separation in an independent colorectal tissue cohort.
Ramadhani Salum Chambuso, Md Shohel Ul Islam, Rosa M Xicola, Raj Ramesar, Xavier Llor, Sinclair Steele   +5 more
wiley   +1 more source

Provider perspectives on self-management of hypertension: a survey of perceptions and clinical pharmacist utilization. [PDF]

BMC Nephrol
Howie C, Al-Masry A, Good MK, Van Eyck P, Wendt L, Geasland K, Kennelty K, Yamada M, Jalal D.   +8 more
europepmc   +1 more source